Compare Amylx Pharmaceuticals Inc (AMLX) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Jumia Technologies AG - ADR — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Jumia Technologies AG - ADR trades at $6.94 (market cap $868.21M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 2.3× Jumia Technologies AG - ADR's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| AMLX | JMIA | |
|---|---|---|
Market Cap | $1.98B | $868.21M |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $14.60 |
52-Week Low | $7.64 | $4.26 |
Enterprise Value | $1.70B | $815.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
JMIA trades at $7.01, up 1.45% today, amid a bearish technical signal and mixed earnings. The company reported Q1 2026 revenue growth of 39% but missed EPS expectations, with a net income margin of -30.79%. Cash flow improved with a net inflow of $21.31M in 2025, and management reaffirmed a 2027 profitability target. The stock shows neutral oscillators but bearish moving averages, with support and resistance clustered around $7.
The outlook hinges on JMIA's path to profitability by 2027, supported by expansion initiatives and partnerships like Starlink. Risks include persistent losses, competitive pressures in African e-commerce, and macroeconomic headwinds. Analyst consensus is strongly bullish with 71% buy ratings, but investors must weigh growth potential against execution risks and current negative returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
